Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications

Ramya Ranganathan^1,*, Shruthilaya Madanmohan^1,*, Akila Kesavan¹, Ganga Baskar¹, Yoganathan Ramia Krishnamoorthy², Roy Santosham³, D Ponraju⁴, Suresh Kumar Rayala², Ganesh Venkatraman<sup>1

1</sup>Department of Human Genetics, Sri Ramachandra University, Porur, ²Department of Biotechnology, Indian Institute of Technology, Madras, ³Department of Radiology and Imaging Sciences, Sri Ramachandra University, Porur, Chennai, ⁴Safety Engineering Division, Nuclear and Engineering Safety Group, Indira Gandhi Center for Atomic Research, Kalpakkam, India

*Authors contributed equally to this work

Abstract: The focus on nanotechnology in cancer treatment and diagnosis has intensified due to the serious side effects caused by anticancer agents as a result of their cytotoxic actions on normal cells. This nonspecific action of chemotherapy has awakened a need for formulations capable of definitive targeting with enhanced tumor-killing. Nanooncology, the application of nanobiotechnology to the management of cancer, is currently the most important area of nanomedicine. Currently several nanomaterial-based drug-delivery systems are in vogue and several others are in various stages of development. Tumor-targeted drug-delivery systems are envisioned as magic bullets for cancer therapy and several groups are working globally for development of robust systems.

Keywords: patient-friendly, drug-delivery systems, cancer, nanomedicine

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.